By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    photo of hands with blue veins
    8 Proven Tips on Finding Difficult Veins
    November 12, 2021
    tips for getting over the pandemic blues
    4 Proven Ways to Get Over the Pandemic Blues
    February 22, 2022
    medical industry innovations
    How is CNC Machining Transforming the Medical Industry?
    June 2, 2022
    Latest News
    Choosing the Right Supplement Manufacturer for Your Brand
    May 1, 2025
    Engineering Temporary Hospitals for Extreme Weather
    April 24, 2025
    How a Level 3 RQF Helps in Health and Social Care
    April 9, 2025
    Breathing Easy: The Impact of Air Conditioning on Indoor Air Quality and Health
    April 6, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    telehealth
    Why Telehealth of Tomorrow Belongs in Your Marketing Plan Today
    March 9, 2016
    Privacy on the Internet–Tracking User History With Cookies and Flash Cookies And More-Use a Program Like CCleaner to Fight Back
    August 23, 2017
    Cosmetic Surgery Under Scrutiny
    September 26, 2011
    Latest News
    The Backbone of Successful Trials: Clinical Data Management
    April 28, 2025
    Advancing Your Healthcare Career through Education and Specialization
    April 16, 2025
    Do Abuse Reporting Systems in Assisted Living Protect Residents’ Health?
    April 15, 2025
    Why Legal Help Is Crucial for Families Affected by Birth Injuries
    April 8, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Treating Cancer – Moving Beyond the Whack-a-Mole Approach
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Treating Cancer – Moving Beyond the Whack-a-Mole Approach
BusinessMedical InnovationsPolicy & LawTechnology

Treating Cancer – Moving Beyond the Whack-a-Mole Approach

Shane Climie
Last updated: September 26, 2011 1:48 pm
Shane Climie
Share
6 Min Read
SHARE

In his latest Wall Street Journal column (“Drugs That Are as Smart as Our Diseases”), biologist/author Matt Ridley bemoans the plummeting efficiency of drug discovery in the pharmaceutical industry. He points to a disturbing paradox: while identifying and sequencing genes of pathogens and cancer cells has become much cheaper in a short period of time, the number of new drug candidates (based at least in part on our knowledge of those genes) has dropped.

In his latest Wall Street Journal column (“Drugs That Are as Smart as Our Diseases”), biologist/author Matt Ridley bemoans the plummeting efficiency of drug discovery in the pharmaceutical industry. He points to a disturbing paradox: while identifying and sequencing genes of pathogens and cancer cells has become much cheaper in a short period of time, the number of new drug candidates (based at least in part on our knowledge of those genes) has dropped. According to Ridley, new molecule approvals per billions of dollars of inflation-adjusted R&D amounts to no more than one percent of the number of approvals in 1950. And as we’re all aware, this decline in innovation is all the more dire because the pharmaceutical industry needs to replace so-called “blockbuster” drugs that are about to lose their patent protections if it is to continue to keep investors satisfied and fuel future innovation.

So, why hasn’t the same industry that gave us statins, Herceptin®, and vaccines come up with a new generation of treatments? The biggest problem might lie in its success. Researchers today confront an enormous—and growing—amount of genetic and biochemical information as the search continues for newer, more effective drugs.  As we generate more data, we are increasing our understanding of the complexity of biological processes underlying disease states.  While this better understanding can lead to innovation, it also has uncovered obstacles. For example, scientists have found that signaling pathways leading to cancers are replete with redundancy, shortcuts and other molecular detours that block the activity of cancer drugs. Sometimes, these pathways can help eliminate or prevent cancer; at other times they can exacerbate it.

It also has become increasingly clear that cancers are not what we originally defined them to be. There are 200 types of cancer; most are defined by the tissue in which they are predominantly found or in which they originated (in the case of metastasis). This location-based classification was useful for surgical solutions (which were once the only options available), and could provide some sense of prognosis. However, these location-based classifications do not capture the biological diversity of cancer.

More Read

Image
3 Promising Mobile Diagnosis Apps for Medical Practitioners
The Cost of Diagnosis: The Sometimes Fatal “Incidentaloma”
Patient Tracking Systems: Improving Facilities for Patients and Medical Staff
A Better Patient Experience Starts With a Better Online Experience
Mobile Phone-Brain Cancer Link Bewilders Epidemiologists

Herceptin® provides a useful glimpse into cancer’s complexity (as well as into the challenges in treating cancer’s manifestations). When introduced, Herceptin proved very effective against breast cancers triggered by mutations in HER2. However, many cancers are resistant to Herceptin, and researchers are now using a “Whack-a-Mole” approach, relying on successive hammer attacks to fight multiple mutations and pathways that pop-up to bypass effects of the “targeted” drug. In fact, Tanizaki and colleagues (full text by subscription) found that HER2, HER3 and MET are factors not only in breast cancer, but lung cancer as well. It’s possible that the “Whack-a-Mole” approach can address the multiple targets that characterize the molecular mechanisms of cancer, while addressing cancers by their genomic and signaling profiles. But that approach will become more effective in those cases where we can simultaneously hit multiple drug targets. It involves taking cancer treatment to the next level.

Clearly, finding the “moles” and utilizing “multiple hammers” will require more and more information, and represents a change in drug discovery strategy from the “one disease-one target” biochemical approach.  The World Health Organization has recommended reclassifying lung cancers (subscription required for full text) by immunohistochemical criteria, for example, and continues to work on expanding definitions of cancers to gene or cell signal.

Revisiting the earlier-raised question of “Why the dearth in a new generation of treatments,” I wonder: Will this change in drug discovery strategy help us develop more effective drugs for cancer patients? Can advances in areas like systems biology find more answers that will lead to new options in the treatment of cancer and other diseases? Can we move beyond the “Whack-a Mole” hammer to make smarter treatments? Please share your thoughts with us here.

 

This post was originally published on the Popper and Co Blog.

TAGGED:cancercancer treatmentdrug discoverygenetics
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

fitness
What Personal Trainers Can & Can’t Say When it Comes to Nutrition
Fitness Wellness
May 12, 2025
online nursing degree
Online FNP Programs Help Advance Your Nursing Career
Career Nursing
May 12, 2025
health effects of poor sleep
The Overlooked Health Cost of Poor Sleep
Wellness
May 7, 2025
medication suppliers
Choosing the Right Supplement Manufacturer for Your Brand
Health
May 1, 2025

You Might also Like

Clinical Trial Marketing, Patient Recruitment, Clinical Trial Recruitment, Patient Engagement
BusinessFinanceTechnology

Can Savvy Marketing Solve the Problem of Low Clinical Trial Recruitment?

August 18, 2014
Healthcare Spending
BusinessFinanceHospital AdministrationPolicy & Law

Healthcare Spending: Administrative Costs out of Control

September 27, 2014
claim denial management
BusinessFinance

When It Comes to Denial Management, Qualitative Data Is Your Best Ally

April 4, 2014

Understanding Physician Shortages Means Asking the Right Questions

September 11, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?